--- title: "Halozyme Therap | 8-K: FY2025 Revenue Beats Estimate at USD 1.397 B" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/276167416.md" datetime: "2026-02-17T21:06:57.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276167416.md) - [en](https://longbridge.com/en/news/276167416.md) - [zh-HK](https://longbridge.com/zh-HK/news/276167416.md) --- > 支持的语言: [English](https://longbridge.com/en/news/276167416.md) | [繁體中文](https://longbridge.com/zh-HK/news/276167416.md) # Halozyme Therap | 8-K: FY2025 Revenue Beats Estimate at USD 1.397 B Revenue: As of FY2025, the actual value is USD 1.397 B, beating the estimate of USD 1.394 B. EPS: As of FY2025, the actual value is USD 2.56, missing the estimate of USD 5.636. EBIT: As of FY2025, the actual value is USD 463.53 M. #### Financial Highlights for Full Year 2025 ##### Revenue - 奥洛兹美医疗 (Halozyme Therapeutics, Inc.) reported total revenue of $1,396.6 million for the full year 2025, marking a 38% year-over-year increase from $1,015.3 million in 2024, primarily driven by increased royalty revenue and product sales . - Royalty revenue reached a record $867.8 million in 2025, a 52% increase from $571.0 million in 2024, mainly due to continued sales uptake of ENHANZE® partner products like VYVGART® Hytrulo, DARZALEX® SC, and Phesgo® . - Product sales, net, were $376,444 thousand in 2025, up from $303,492 thousand in 2024 . - Revenues under collaborative agreements were $152,327 thousand in 2025, compared to $140,841 thousand in 2024 . ##### Operating Costs and Expenses - Cost of Sales increased to $228.8 million in 2025 from $159.4 million in 2024, primarily due to higher product sales and labor allocation initiatives . - Amortization of Intangibles Expense rose to $76.7 million in 2025 from $71.0 million in 2024, attributed to the acquisition of Elektrofi in November 2025 . - Research and Development Expense increased to $81.5 million in 2025 from $79.0 million in 2024, mainly due to the acquisitions of Elektrofi and Surf Bio . - Selling, General and Administrative Expense grew to $207.1 million in 2025 from $154.3 million in 2024, driven by increased consulting and professional service fees, litigation costs, and transaction-related costs for acquisitions . - Impairment of Intangible Asset was $48,700 thousand in 2025, with no comparable amount in 2024 . - Acquired In-Process Research and Development (IPR&D) Expense was $284.9 million in 2025, related to the Surf Bio acquisition in the fourth quarter . - Total Operating Expenses were $927,605 thousand in 2025, compared to $463,849 thousand in 2024 . ##### Profitability - Operating Income was $469,006 thousand in 2025, a decrease from $551,475 thousand in 2024 . - Net Income decreased to $316.9 million in 2025 from $444.1 million in 2024, impacted by $284.9 million in acquired IPR&D expense . - Adjusted EBITDA increased to $657.6 million in 2025 from $632.2 million in 2024 . ##### Cash and Liquidity - Cash, cash equivalents, restricted cash and marketable securities totaled $145.4 million as of December 31, 2025, a decrease from $596.1 million as of December 31, 2024 . This decrease was primarily due to cash used for the Elektrofi and Surf Bio acquisitions and share repurchases, partially offset by net proceeds from convertible notes issuance and cash generated from operations . #### Financial Highlights for Fourth Quarter 2025 ##### Revenue (Q4 2025 vs. Q4 2024) - Total Revenue was $451.8 million, a 52% increase from $298.0 million . - Royalty Revenue was $258.0 million, a 51% increase from $170.4 million . ##### Profitability (Q4 2025 vs. Q4 2024) - Net Loss was - $141.6 million, compared to a net income of $137.0 million in the prior year quarter, largely due to $284.9 million in acquired IPR&D expense . - Adjusted EBITDA was $21.9 million, down from $195.8 million . #### Outlook / Guidance for 2026 奥洛兹美医疗 (Halozyme Therapeutics, Inc.) projects total revenue between $1.710 billion and $1.810 billion for 2026, representing 22% to 30% growth over 2025 . Royalty revenue is expected to range from $1.130 billion to $1.170 billion, a 30% to 35% increase . Adjusted EBITDA is forecasted to reach $1.125 billion to $1.205 billion, reflecting 71% to 83% growth, including approximately $60 million in new Hypercon™ and Surf Bio investments . ### 相关股票 - [Halozyme Therap (HALO.US)](https://longbridge.com/zh-CN/quote/HALO.US.md) ## 相关资讯与研究 - [Granite Investment Partners LLC Lowers Holdings in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/zh-CN/news/268396301.md) - [Halozyme Therapeutics Says Johnson & Johnson Wins FDA Approval for Blood Cancer Treatment](https://longbridge.com/zh-CN/news/278116099.md) - [Key facts: Bunge Increases Securitization to $2.0B; 8-K on Obligation](https://longbridge.com/zh-CN/news/281659964.md) - [Lawson Kroeker Investment Management Inc. NE Sells 80,550 Shares of Bruker Corporation $BRKR](https://longbridge.com/zh-CN/news/281682127.md) - [Jushi Posts Modest 2025 Revenue Growth, Extends Debt Maturities to 2029](https://longbridge.com/zh-CN/news/281275002.md)